Miromatrix Medical Added to Russell Microcap® Index

Rhea-AI Summary

Miromatrix Medical Inc. (NASDAQ: MIRO) has been added to the Russell Microcap® Index, effective September 20, 2021. This inclusion aims to enhance its visibility and investor exposure as the company develops bioengineered organs. CEO Jeff Ross expressed optimism regarding the timing, noting the upcoming submission of an IND for a Phase I Liver Assist Trial in the first half of 2022. The Russell Microcap Index comprises the smallest securities from the Russell 2000® Index and is crucial for investors, with approximately $9 trillion in assets benchmarked to these indexes.

Positive

• Inclusion in the Russell Microcap Index increases visibility and investor exposure.
• Upcoming submission of an IND for the Phase I Liver Assist Trial is a significant milestone.

Negative

• None.

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market opens today, September 20, 2021.

The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000® Index, plus the next 1,000 smallest eligible securities by market cap. The Index is completely reconstituted annually to ensure new and growing equities are reflected and companies continue to reflect appropriate capitalization and value characteristics.

"We are honored and thrilled to be a part of the Russell Microcap Index, and we believe the inclusion will increase our visibility and exposure with investors," said Jeff Ross, Ph.D., Miromatrix CEO. "The inclusion in the Russell Microcap Index comes at an important time for Miromatrix, as we continue to advance our proprietary bioengineered organ technology towards submitting an IND with the FDA in the first half of 2022 for our Phase I Liver Assist Trial."

Approximately $9 trillion in assets under management (AUM) are benchmarked to or invested in products based on the Russell US Indexes, underscoring the importance of reconstitution to investors and the markets. In addition, $16 trillion in assets are currently benchmarked to indexes offered by FTSE Russell.

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About Miromatrix

Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com

FAQ

When did Miromatrix get added to the Russell Microcap Index?

Miromatrix was added to the Russell Microcap Index on September 20, 2021.

What is the significance of the Russell Microcap Index for Miromatrix?

Inclusion in the Russell Microcap Index enhances Miromatrix's visibility and exposure to investors.

What are Miromatrix's future plans following its Russell Microcap Index inclusion?

Miromatrix plans to submit an IND for its Phase I Liver Assist Trial in the first half of 2022.

How much assets are benchmarked to the Russell US Indexes?

Approximately $9 trillion in assets are benchmarked to the Russell US Indexes.